raltegravir-Amideimpurity

Raltegravir-Amideimpurity is a structurally related impurity derived from the parent HIV integrase inhibitor raltegravir, characterized by a substituted naphthyridine core linked to a cyclopropylmethyl group via an amide moiety. The compound retains the 4-amino-1-ethyl-2,6-dimethyl framework but exhibits altered substituent patterns at the amide linkage, resulting in distinct HPLC retention and mass spectral properties. This impurity arises during synthetic processes due to partial acyl substitution and serves as a critical reference standard for HPLC method validation to quantify process-related amide variants in raltegravir drug substance batches.